Decoy Therapeutics Inc. regained compliance with Nasdaq's Minimum Bid Price Requirement following a reverse stock split, with confirmation on March 31, 2026, and will be subject to a Mandatory Panel Monitor until March 31, 2027.
Key takeaways
Company received Nasdaq non-compliance notice on December 31, 2025, for bid price below $1.00 for 30 consecutive business days.
Implemented reverse stock split effective March 6, 2026, trading on split-adjusted basis from March 9, 2026.
Hearings Panel granted exception period until March 20, 2026, to achieve $1.00 bid price for 10 consecutive business days.
Common stock closed at $7.47 on March 20, 2026, meeting compliance requirement.
Nasdaq confirmed full compliance with all listing requirements on March 31, 2026.
Subject to Mandatory Panel Monitor until March 31, 2027, with potential delisting hearing if non-compliant.